-
Interpretation of A Focus Shift From Sarcopenia to Muscle Health in the Asian Working Group for Sarcopenia 2025 Consensus Update
-
Loneliness and sarcopenia in aged care: the mediating role of fatigability
-
The Role of Extracellular Vesicles MicroRNAs in Sarcopenia: From Aging to Multi‐Morbidity
-
Sarcopenia and Its Relationships with Depression, Cognition, and Physical Activity in Thai Community-Dwelling Older Adults
-
Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
-
Sarcopenia: Influence of Regional Skeletal Muscle Cutoff Points and Fat-Free Mass in Older Mexican People—A Pilot Study
-
Determining the Protective Effects of Long‐Term Physical Activity, Exercise, Mental Health, and Employment on Sarcopenia—A Result of a Feasibility Study of a Registry
-
Biodemographic Analyses of Longitudinal Data on Aging, Health, and Longevity: Recent Advances and Future Perspectives
-
Heritability of Alzheimer's disease–related plasma biomarkers in the Amish population
-
Performing multiple biomarker tests delays initiation of amyloid‐targeting treatments
-
Identifying populations with faster cognitive decline using blood‐based biomarkers
-
APOE ε4 and Alzheimer's disease biomarkers in an American Indian community
-
A fovea‐centered retinal signature linked to plasma biomarkers in prodromal Alzheimer's disease
-
CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
-
Perceptions of the use of biomarkers for Alzheimer's disease diagnosis: A systematic review and synthesis of the qualitative literature
-
The effect of treating hearing loss with hearing aids on plasma biomarkers of Alzheimer's disease and related dementias
-
Short‐term psychological impacts of Alzheimer's disease risk disclosure based on blood‐biomarker results
-
Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
-
Cerebrospinal fluid NPTX2/p‐tau ratio as a biomarker for cognitive decline in neurodegenerative diseases
-
Physical activity attenuates the association between allostatic load and early Alzheimer's disease‐related biomarkers in older adults
-
Defining Aging: Past, Present, and Possible Future
-
A potential multimodal biomarker – cognitive signature associated with the conversion from subjective cognitive decline to mild cognitive impairment
-
A diagnostic plasma omics‐biomarker for Alzheimer's disease informed by microglial single‐cell transcriptomics: A pilot study
-
Nasogastric Tube Feeding in Older Patients: A Review of Current Practice and Challenges Faced
